
Lysiane Marthey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9325972/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	10.7	719
2	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 395-401.	1.3	274
3	Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut, 2018, 67, 2056-2067.	12.1	179
4	Olmesartan-associated enteropathy: results of a national survey. Alimentary Pharmacology and Therapeutics, 2014, 40, 1103-1109.	3.7	166
5	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. British Journal of Cancer, 2015, 113, 989-995.	6.4	151
6	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. Annals of Surgical Oncology, 2015, 22, 295-301.	1.5	145
7	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE,) Tj ETQq1 1	0.784314 0.9	rgBT/Over
8	Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 852-859.	6.4	77
9	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clinical Gastroenterology and Hepatology, 2020, 18, 1393-1403.e1.	4.4	47
10	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. European Journal of Cancer, 2019, 106, 106-114.	2.8	41
11	Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. European Journal of Cancer, 2019, 119, 35-43.	2.8	24
12	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. British Journal of Cancer, 2018, 119, 424-428.	6.4	22
13	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. British Journal of Cancer, 2021, 124, 1941-1948.	6.4	20
14	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Digestive and Liver Disease, 2016, 48, 441-445.	0.9	17
15	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101603.	1.5	12
16	Letter: sprueâ€like enteropathy associated with angiotensin <scp>II</scp> receptor blockers other than olmesartan—authors'reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 473-474.	3.7	0
17	P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI). Journal of Crohn's and Colitis, 2018, 12, S289-S290.	1.3	0